Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Cash Flows

v3.23.2
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows from Operating Activities:    
Net loss $ (114,446) $ (103,408)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation expense 1,476 1,495
Loss on disposal of property and equipment 0 239
Bad debt expense (recovery) 574 (45)
Amortization of debt discount 1,867 946
Accretion of partner company convertible preferred shares 521 0
Non-cash interest 176 418
Loss on extinguishment of debt 2,796 0
Amortization of acquired intangible assets 2,138 2,034
Reduction in the carrying amount of operating lease right-of-use assets 1,052 889
Stock-based compensation expense 8,948 10,644
Issuance (reversal) of partner company's common shares for research and development expenses 1,233 (35)
Common shares issued/issuable for dividend on partner company's convertible preferred shares 131 0
Change in fair value of partner companies' warrant liabilities (6,166) 0
Research and development-licenses acquired, expense 3,000 0
Loss from deconsolidation of Aevitas 3,369 0
Asset impairment loss 2,923 0
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:    
Accounts receivable 10,897 (5,514)
Inventory 1,993 (150)
Other receivables - related party (135) 302
Prepaid expenses and other current assets 2,243 1,946
Other assets (97) 31
Accounts payable and accrued expenses 433 4,197
Deferred revenue (364) (1,154)
Income taxes payable 1 0
Lease liabilities (980) (1,026)
Other long-term liabilities (94) (93)
Net cash used in operating activities (76,511) (88,284)
Cash Flows from Investing Activities:    
Purchase of research and development licenses (2,000) 0
Purchase of property and equipment (34) (1,644)
Deconsolidation of Aevitas (5) 0
Acquired intangible assets (5,000) (20,000)
Net cash used in investing activities (7,039) (21,644)
Cash Flows from Financing Activities:    
Payment of Series A perpetual preferred stock dividends (4,016) (4,016)
Proceeds from issuance of common stock for public offering, net 13,248 0
Proceeds from issuance of common stock for at-the-market offering, net 1,168 5,527
Proceeds from issuance of common stock under ESPP 0 99
Proceeds from partner companies' ESPP 88 116
Partner company's dividends declared and paid (371) (375)
Proceeds from partner companies' sale of stock and warrants, net 24,455 0
Proceeds from partner companies' at-the-market offering, net 0 14,476
Proceeds from exercise of partner companies' equity grants 3 111
Partner company's net settlement of shares withheld for taxes 0 (1,698)
Repayment of partner company installment payments - licenses 0 (2,000)
Proceeds from partner company convertible preferred shares 854 0
Payment of costs related to partner company's sale of stock 0 (371)
Payment of debt issuance costs associated with partner company convertible preferred shares (210) (214)
(Repayment of) Proceeds from partner company long-term debt, net (90) 42,112
Repayment of partner company long-term debt (40,375) 0
Proceeds from partner company's line of credit 28,000 0
Repayment of partner company's line of credit (30,948) (812)
Net cash provided by financing activities (8,194) 52,955
Net decrease in cash and cash equivalents and restricted cash (91,744) (56,973)
Cash and cash equivalents and restricted cash at beginning of period 180,954 307,964
Cash and cash equivalents and restricted cash at end of period 89,210 250,991
Supplemental disclosure of cash flow information:    
Cash paid for interest 5,131 3,987
Cash paid (refunded) for tax (52) 166
Supplemental disclosure of non-cash financing and investing activities:    
Settlement of restricted stock units into common stock 3 3
Unpaid fixed assets 0 315
Partner company's unpaid intangible assets 0 4,740
Unpaid partner company's debt offering cost 0 1,050
Unpaid partner company's offering cost 246 0
Partner company derivative warrant liability associated with partner company convertible preferred shares 33 0
Warrants 0 384
Prepaid public offering cost 94 0
Unpaid public offering cost 0 0
Transfer of assets classified as held for sale $ 4,348 $ 0